Tonix scraps Covid-19 li­cens­ing deal af­ter just three months — shares spike

Pen­ny stock biotech Tonix Phar­ma­ceu­ti­cals re­port­ed in an SEC fil­ing Mon­day that it was end­ing a li­cens­ing deal with New York in­fec­tious dis­ease and on­col­o­gy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER